A panelist discusses how folate receptor alpha (FRα) expression testing plays a crucial role in determining eligibility for ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

WuXi XDC is trading at a price-to-earnings (P/E) ratio of 32 times, a significant premium over WuXi AppTec's 14 times.

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

The Abu Dhabi health care company M42 is to make an investment in biotech longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a partnership ...

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

Antibody-drug conjugate developer Duality Biotherapeutics Inc. debuted on the Hong Kong Stock Exchange (HKEX) with a HK$1.64 billion (US$211.4 million) IPO April 15, making it one of the biggest ...

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...